S885 Safety of Ustekinumab in Older IBD Patients (≥60 Years): Pooled Safety Analysis Through 5 Years in CD and 2 Years in UC and All Approved Indications

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalAmerican Journal of Gastroenterology
DOIs
Publication statusPublished - 2021

Keywords

  • Medicine
  • Ustekinumab
  • Adverse effect
  • Inflammatory bowel disease
  • Ulcerative colitis
  • Psoriatic arthritis
  • Internal medicine
  • Psoriasis
  • Safety profile
  • Disease
  • Infliximab
  • Dermatology

Cite this